Skip to main content
. 2020 Nov 16;39(9):966–977. doi: 10.1200/JCO.20.00892

FIG 4.

FIG 4.

Time to and duration of response (investigator assessed per RECIST [version 1.1]) during the maintenance phase (after random assignment) in (A) avelumab and (B) chemotherapy arms. Responses were based on subsequent change after random assignment (during maintenance) in patients who had achieved partial response (PR) or stable disease (SD) after induction chemotherapy. Excludes 10 patients with complete response (CR) during induction chemotherapy. NR, not reached; PD, progressive disease.